(Q35832295)

10 August 2017

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years (English)

1 reference

triple-negative breast cancer

10 August 2017

1 reference

N Rahman

15

0 references

Richard Houlston

object named as

R Houlston

8

0 references

Clare Turnbull

7

object named as

C Turnbull

1 reference

10 August 2017

13

D Eccles

1 reference

ORCID Public Data File 2021

10 August 2017

1 reference

author name string

L Robertson

1

1 reference

10 August 2017

H Hanson

2

1 reference

10 August 2017

S Seal

3

1 reference

10 August 2017

M Warren-Perry

4

1 reference

10 August 2017

D Hughes

5

1 reference

10 August 2017

I Howell

6

1 reference

10 August 2017

S Shanley

9

1 reference

10 August 2017

S Butler

10

1 reference

10 August 2017

D G Evans

11

1 reference

10 August 2017

G Ross

12

1 reference

10 August 2017

A Tutt

14

1 reference

10 August 2017

TNT Trial TMG

16

1 reference

10 August 2017

BCSC (UK)

17

1 reference

10 August 2017

language of work or name

English

0 references

publication date

14 February 2012

1 reference

British Journal of Cancer

10 August 2017

1 reference

10 August 2017

106

1 reference

10 August 2017

6

1 reference

10 August 2017

1234-1238

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

10 August 2017

1 reference

Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Triple-Negative Breast Cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Therapeutic approaches for women predisposed to breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Incorporating tumour pathology information into breast cancer risk prediction algorithms

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

11 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.31

Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.31

Update on the Manchester Scoring System for BRCA1 and BRCA2 testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.31

'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.31

Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304410

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

24 September 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.31

Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.31

Expanding the Criteria forBRCAMutation Testing in Breast Cancer Survivors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22333603

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2012.31

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22333603

1 reference